IL17A and Chronic colitis: The feasibility of the proposed mechanism of probiotic inhibition of IL-17 target is supported by a comparative study showing 4SC-101 [83] and Vidofludimus [84], both novel immunosuppressive drugs, inhibit IL-17 and attenuates chronic colitis in mice.